Skip to content
Screener

Cytek Biosciences, Inc. CTKB Business Segments — Total revenue, net

Similar metrics at other companies

Evolus logo
EOLSReportable Segment — Total net revenues
$84.08M+21.2%
DocuSign logo
DOCUReportable Segment — Total Revenue
$830.24M+8.7%
Guidewire Software logo
GWREReportable Segment — Total Revenue
$372.54M+26.9%
UiPath logo
PATHReportable Segment — Total Revenue
$418.38M+17.3%
Andersen Group logo
ANDGReportable Segment — Total Revenue
$240.75M+15.7%
Lemonade logo
LMNDReportable Segment — Total Revenue
$258M+70.6%

Other financials

Income statement

See full
Revenue$48.1M+5.6%
Gross profit$28.3M+18.7%
Operating income-$11.4M-7.3%
Net income-$12.2M-118%
EPS (diluted)-$0.09-125%

Balance sheet

See full
Cash & equivalents$73.8M-2.2%
Total debt$17.0M-6.6%
Total equity$322.0M-14.7%
Total assets$446.9M-9.4%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+40.5%
Free cash flow-$849.0K+42.2%

Valuation

See full
Market cap$545.93M+25.6%
Enterprise value$489.11M+29.2%
P/S2.6×+0.4×

Profitability

See full
Gross margin53.2%-1.2pp
Operating margin-21.6%
Net margin-39%
FCF margin-5.8%-11.4pp

Returns & leverage

See full
Return on equity-23%
Debt / equity0.1×0.0×
Current ratio4.5×-0.7×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053496
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue, net:
Product$32,556$31,415$61,335$59,525
Service15,58414,18730,94027,534
Total revenue, net$48,140$45,602$92,275$87,059
Cost of sales (excluding stock-based compensation)18,58420,14440,25539,865
Amortization - license & IP expense481481962974
Sales (excluding stock-based compensation)9,0427,83217,85516,438
Marketing (excluding stock-based compensation)3,3573,0665,4115,765

Item 1. Consolidated Financial Statements (Unaudited)

FAQ

What is Cytek Biosciences, Inc.'s business segments — total revenue, net?
Cytek Biosciences, Inc. (CTKB) reported business segments — total revenue, net of $48.14M in Q2 2026.
How has Cytek Biosciences, Inc.'s business segments — total revenue, net changed year-over-year?
Cytek Biosciences, Inc.'s business segments — total revenue, net increased by 5.6% year-over-year, from $45.6M to $48.14M.
What is the long-term trend for Cytek Biosciences, Inc.'s business segments — total revenue, net?
Over 3 years (2022 to 2025), Cytek Biosciences, Inc.'s business segments — total revenue, net has grown at a 7.1% compound annual growth rate (CAGR), from $164.04M to $201.49M.
What does business segments — total revenue, net mean?
Represents the total net sales generated by the primary business segment after deducting returns, allowances, and discounts. This figure serves as the top-line indicator of market demand for the company's core products and services.

Ask your AI about Cytek Biosciences, Inc.'s business segments — total revenue, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude